Patient characteristics
| CT | TT | ICI | |||||||
| SARS-CoV-2 negative n=37 | SARS-CoV-2 positive n=13 | Overall n=50 | SARS-CoV-2 negative n=60 | SARS-CoV-2 positive n=24 | Overall n=84 | SARS-CoV-2 negative n=107 | SARS-CoV-2 positive n=52 | Overall n=159 | |
| Age | |||||||||
| Mean (SD) | 66.3 (11.7) | 63.2 (14.2) | 65.5 (12.4) | 62.3 (13.7) | 61.6 (12.8) | 62.1 (13.4) | 66.3 (12.5) | 66.9 (11.3) | 66.5 (12.1) |
| Median (Q1–Q3) | 69.0 (61.0–75.0) | 65.0 (58.0–73.0) | 67.5 (58.0–75.0) | 65.0 (54.5–72.5) | 63.5 (53.5–70.0) | 63.5 (54.5–71.5) | 69.0 (59.0–75.0) | 68.0 (62.0–73.5) | 69.0 (60.0–75.0) |
| Min–Max | 26.0–84.0 | 26.0–81.0 | 26.0–84.0 | 28.0–88.0 | 31.0–84.0 | 28.0–88.0 | 20.0–89.0 | 39.0–86.0 | 20.0–89.0 |
| Sex | |||||||||
| Female | 12 (32.4) | 4 (30.8) | 16 (32.0) | 33 (55.0) | 10 (41.7) | 43 (51.2) | 36 (33.6) | 16 (30.8) | 52 (32.7) |
| Male | 25 (67.6) | 9 (69.2) | 34 (68.0) | 27 (45.0) | 14 (58.3) | 41 (48.8) | 71 (66.4) | 36 (69.2) | 107 (67.3) |
| Number of subjects with at least one comorbidity other than cancer | 25 (67.6) | 8 (61.5) | 33 (66.0) | 32 (53.3) | 11 (45.8) | 43 (51.2) | 60 (56.1) | 28 (53.8) | 88 (55.3) |
| Description of comorbidities: | |||||||||
| Number of comorbidities (n%) | |||||||||
| One comorbidity | 17 (68.0) | 6 (75.0) | 23 (69.7) | 24 (75.0) | 7 (63.6) | 31 (72.1) | 39 (65.0) | 21 (75.0) | 60 (68.2) |
| More than one comorbidity | 8 (32.0) | 2 (25.0) | 10 (30.3) | 8 (25.0) | 4 (36.4) | 12 (27.9) | 21 (35.0) | 7 (25.0) | 28 (31.8) |
| Number of patients with cardiac disease | 17 (68.0) | 5 (62.5) | 22 (66.7) | 24 (75.0) | 8 (72.7) | 32 (74.4) | 45 (75.0) | 26 (92.9) | 71 (80.7) |
| Number of patients with pulmonary disease | 6 (24.0) | 4 (50.0) | 10 (30.3) | 8 (25.0) | 4 (36.4) | 12 (27.9) | 22 (36.7) | 2 (7.1) | 24 (27.3) |
| Number of patients with chronic kidney disease | 2 (8.0) | 1 (12.5) | 3 (9.1) | 5 (15.6) | 0 (0.0) | 5 (11.6) | 5 (8.3) | 2 (7.1) | 7 (8.0) |
| Number of patients with diabetes | 7 (28.0) | 1 (12.5) | 8 (24.2) | 2 (6.3) | 3 (27.3) | 5 (11.6) | 16 (26.7) | 6 (21.4) | 22 (25.0) |
| Number of patients with underlying immunodeficiency | 2 (8.0) | 0 (0.0) | 2 (6.1) | 2 (6.3) | 0 (0.0) | 2 (4.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cancer details | |||||||||
| Cancer type | |||||||||
| Melanoma | 0 (0.0) | 0 (0.0) | 0 (0.0) | 34 (56.7) | 18 (75.0) | 52 (61.9) | 54 (50.5) | 37 (71.2) | 91 (57.2) |
| NSCLC | 20 (54.1) | 9 (69.2) | 29 (58.0) | 15 (25.0) | 3 (12.5) | 18 (21.4) | 43 (40.2) | 10 (19.2) | 53 (33.3) |
| RCC | 1 (2.7) | 2 (15.4) | 3 (6.0) | 9 (15.0) | 3 (12.5) | 12 (14.3) | 7 (6.5) | 5 (9.6) | 12 (7.5) |
| Other | 16 (43.2) | 2 (15.4) | 18 (36.0) | 2 (3.3) | 0 (0.0) | 2 (2.4) | 3 (2.8) | 0 (0.0) | 3 (1.9) |
| Cancer stage (AJCC v8) | |||||||||
| III | 6 (16.2) | 4 (30.8) | 10 (20.0) | 11 (18.3) | 4 (16.7) | 15 (17.9) | 25 (23.4) | 15 (28.8) | 40 (25.2) |
| IV | 31 (83.8) | 9 (69.2) | 40 (80.0) | 49 (81.7) | 20 (83.3) | 69 (82.1) | 82 (76.6) | 37 (71.2) | 119 (74.8) |
.AJCC, american joint committee on cancer; CT, chemotherapy; ICI, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; Q1, first quartile; Q3, third quartile; RCC, renal cell carcinoma; TT, targeted therapy.